Gavreto ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

gavreto

roche registration gmbh  - pralsetinib - karsinom, ikke-småcellet lunge - antineoplastiske midler - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

Dasatinib Accord ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

dasatinib accord

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Dasatinib Accordpharma ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

dasatinib accordpharma

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Dasatinib Teva 70 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

dasatinib teva 70 mg

teva b.v. - dasatinibmonohydrat - tablett, filmdrasjert - 70 mg

Dasatinib Teva 20 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

dasatinib teva 20 mg

teva b.v. - dasatinibmonohydrat - tablett, filmdrasjert - 20 mg

Dasatinib Teva 50 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

dasatinib teva 50 mg

teva b.v. - dasatinibmonohydrat - tablett, filmdrasjert - 50 mg

Dasatinib Sandoz 70 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

dasatinib sandoz 70 mg

sandoz - københavn - dasatinib - tablett, filmdrasjert - 70 mg

Dasatinib Sandoz 20 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

dasatinib sandoz 20 mg

sandoz - københavn - dasatinib - tablett, filmdrasjert - 20 mg

Dasatinib Sandoz 50 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

dasatinib sandoz 50 mg

sandoz - københavn - dasatinib - tablett, filmdrasjert - 50 mg

Mekinist ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

mekinist

novartis europharm limited - trametinib - melanom - antineoplastiske midler - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. non-small cell lung cancer (nsclc)trametinib i kombinasjon med dabrafenib er indisert for behandling av voksne pasienter med avansert non-small cell lung cancer med en braf v600 mutasjon.